BioInsights - Capsid titre quantification for AAV-based therapeutics
Jan
30
2020
On demand

Capsid titre quantification for AAV-based therapeutics

Sponsor
Capsid titre quantification for AAV-based therapeutics

Cell and gene therapies require development of fit for purpose analytical tools to support bioprocess development, for biopharmaceutical characterization and lot release testing. In AAV-based therapeutics content methods measure the number of viral genomes (genome titre) and the number of viral particles (capsid titre) per volume unit. While the former is easily quantified by PCR-based techniques, the latter poses some challenges. Here, we present an immunoassay developed on the Gyrolab® platform with AAV serotype-specific antibodies that can reliably measure AAV capsid titre in purified and in process samples making it suitable for AAV process development. Versatility of this assay is based on using an antibody pair, where one antibody recognises a broad spectrum of AAV serotypes and the other is serotype specific. This assay setup can be readily adapted to titre measurements of various AAV serotypes and has a greater quantification range compared to a commercially available capsid ELISA kit.

The audience will find out how:

  • Gyrolab technology can be used for AAV capsid titre quantification
  • The experimental setup can be modified for testing many different AAV serotypes
  • The developed immunoassay can be used for measuring purified AAV as well as in-process samples

By registering for the webinar, I agree to receive information from Gyros Protein Technologies. By following relevant data privacy laws (GDPR), Gyros Protein Technologies will process my personal data in line with its privacy policy, which can be reviewed at http://www.gyrosproteintechnologies.com/privacy. I can choose to unsubscribe at any time by e-mailing information@gyrosproteintech.com


John Chappell
John Chappell
Application and Service Director, EMEA at Gyros Protein Technologies
Tomasz  Witkos
Tomasz Witkos
Scientist at AstraZeneca

SPEAKERS

John Chappell
John Chappell
Application and Service Director, EMEA at Gyros Protein Technologies
Tomasz  Witkos
Tomasz Witkos
Scientist at AstraZeneca

You might also like